55 related articles for article (PubMed ID: 24456412)
1. Odanacatib: a review of its potential in the management of osteoporosis in postmenopausal women.
Chapurlat RD
Ther Adv Musculoskelet Dis; 2015 Jun; 7(3):103-9. PubMed ID: 26029271
[TBL] [Abstract][Full Text] [Related]
2. Odanacatib, a new drug for the treatment of osteoporosis: review of the results in postmenopausal women.
Pérez-Castrillón JL; Pinacho F; De Luis D; Lopez-Menendez M; Dueñas Laita A
J Osteoporos; 2010 Jun; 2010():. PubMed ID: 20948576
[TBL] [Abstract][Full Text] [Related]
3. DANCR Mediates the Rescuing Effects of Sesamin on Postmenopausal Osteoporosis Treatment via Orchestrating Osteogenesis and Osteoclastogenesis.
Yang Z; Feng L; Wang H; Li Y; Lo JHT; Zhang X; Lu X; Wang Y; Lin S; Tortorella MD; Li G
Nutrients; 2021 Dec; 13(12):. PubMed ID: 34960006
[TBL] [Abstract][Full Text] [Related]
4. A novel approach to inhibit bone resorption: exosite inhibitors against cathepsin K.
Panwar P; Søe K; Guido RV; Bueno RV; Delaisse JM; Brömme D
Br J Pharmacol; 2016 Jan; 173(2):396-410. PubMed ID: 26562357
[TBL] [Abstract][Full Text] [Related]
5. Structural basis of collagen fiber degradation by cathepsin K.
Aguda AH; Panwar P; Du X; Nguyen NT; Brayer GD; Brömme D
Proc Natl Acad Sci U S A; 2014 Dec; 111(49):17474-9. PubMed ID: 25422423
[TBL] [Abstract][Full Text] [Related]
6. Odanacatib for the treatment of postmenopausal osteoporosis.
Chapurlat RD
Expert Opin Pharmacother; 2014 Jan; 15(1):97-102. PubMed ID: 24156249
[TBL] [Abstract][Full Text] [Related]
7. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial.
Brixen K; Chapurlat R; Cheung AM; Keaveny TM; Fuerst T; Engelke K; Recker R; Dardzinski B; Verbruggen N; Ather S; Rosenberg E; de Papp AE
J Clin Endocrinol Metab; 2013 Feb; 98(2):571-80. PubMed ID: 23337728
[TBL] [Abstract][Full Text] [Related]
8. Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial.
Bone HG; Dempster DW; Eisman JA; Greenspan SL; McClung MR; Nakamura T; Papapoulos S; Shih WJ; Rybak-Feiglin A; Santora AC; Verbruggen N; Leung AT; Lombardi A
Osteoporos Int; 2015 Feb; 26(2):699-712. PubMed ID: 25432773
[TBL] [Abstract][Full Text] [Related]
9. Odanacatib: an emerging novel treatment alternative for postmenopausal osteoporosis.
Schultz TC; Valenzano JP; Verzella JL; Umland EM
Womens Health (Lond); 2015 Nov; 11(6):805-14. PubMed ID: 26344800
[TBL] [Abstract][Full Text] [Related]
10. Odanacatib for the treatment of osteoporosis.
Boggild MK; Gajic-Veljanoski O; McDonald-Blumer H; Ridout R; Tile L; Josse R; Cheung AM
Expert Opin Pharmacother; 2015; 16(11):1717-26. PubMed ID: 26149759
[TBL] [Abstract][Full Text] [Related]
11. Treatment of postmenopausal osteoporosis with odanacatib.
Chapurlat RD
Expert Opin Pharmacother; 2014 Mar; 15(4):559-64. PubMed ID: 24456412
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
